Literature DB >> 11063607

Active site binding modes of HIV-1 integrase inhibitors.

C A Sotriffer1, H Ni, J A McCammon.   

Abstract

Using the crystal structure of the first complex of the HIV-1 integrase catalytic core domain with an inhibitor bound to the active site, structural models for the interaction of various inhibitors with integrase were generated by computational docking. For the compound of the crystallographic study, binding modes unaffected by crystal packing have recently been proposed. Although a large search region was used for the docking simulations, the ligands investigated here are found to bind preferably in similar ways close to the active site. The binding site is formed by residues 64-67, 116, 148, 151-152, 155-156, and 159, as well as by residue 92 in case of the largest ligand of the series. The coherent picture of possible interactions of small-molecule inhibitors at the active site provides an improved basis for structure-based ligand design. The recurring motif of tight interaction with the two lysine residues 156 and 159 is suggested to be of prime importance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063607     DOI: 10.1021/jm000194t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Efficient docking of peptides to proteins without prior knowledge of the binding site.

Authors:  Csaba Hetényi; David van der Spoel
Journal:  Protein Sci       Date:  2002-07       Impact factor: 6.725

2.  Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: part II. integrase inhibition.

Authors:  Sylvia Lee-Huang; Philip Lin Huang; Dawei Zhang; Jae Wook Lee; Ju Bao; Yongtao Sun; Young-Tae Chang; John Zhang; Paul Lee Huang
Journal:  Biochem Biophys Res Commun       Date:  2007-01-22       Impact factor: 3.575

3.  Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors.

Authors:  Deborah J Lee; W Edward Robinson
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  Mechanism of isoproturon resistance in Phalaris minor: in silico design, synthesis and testing of some novel herbicides for regaining sensitivity.

Authors:  Durg Vijay Singh; Kuruba Adeppa; Krishna Misra
Journal:  J Mol Model       Date:  2011-07-15       Impact factor: 1.810

6.  Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors.

Authors:  Pawan Gupta; Prabha Garg; Nilanjan Roy
Journal:  Mol Divers       Date:  2011-02-15       Impact factor: 2.943

7.  Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.

Authors:  Rajeshri G Karki; Yun Tang; Terrence R Burke; Marc C Nicklaus
Journal:  J Comput Aided Mol Des       Date:  2005-06-27       Impact factor: 3.686

8.  Curcuminoids as inhibitors of thioredoxin reductase: a receptor based pharmacophore study with distance mapping of the active site.

Authors:  Durg Vijay Singh; Krishna Misra
Journal:  Bioinformation       Date:  2009-10-24

9.  Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Authors:  Devendra K Dhaked; Jitender Verma; Anil Saran; Evans C Coutinho
Journal:  J Mol Model       Date:  2008-12-02       Impact factor: 1.810

10.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.